scholarly journals Increased Serum Level and High Tissue Immunoexpression of Interleukin 17 in Cutaneous Lichen Planus: A Novel Therapeutic Target for Recalcitrant Cases?

2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
Magdalena Żychowska ◽  
Aleksandra Batycka-Baran ◽  
Wojciech Baran
Keyword(s):  
Serum Level ◽  
Serum Concentration ◽  
Healthy Volunteers ◽  
Lichen Planus ◽  
Elevated Serum ◽  
Tissue Expression ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Interleukin 17 ◽  
Tissue Samples

Background. Interleukin-17 is supposed to play an important role in the pathogenesis of oral lichen planus (OLP). However, there is scarce data in the literature on its significance in the cutaneous variant of the disease. Objectives. To determine the serum level and tissue immunoexpression of IL-17 in cutaneous lichen planus (CLP). Methods. Fifty-two adult patients with CLP, without any significant autoimmune or inflammatory conditions, were included in the first part of the study. The control group consisted of 27 age- and sex-matched healthy volunteers. Serum concentration of IL-17 was quantified using enzyme-linked immunosorbent assay (ELISA) kit. In the second part of the study, the tissue expression of IL-17 was assessed in archival paraffin-embedded biopsy specimens from CLP (n=14) against normal control tissues (n=11) using immunohistochemical assays. The expression was evaluated using Zeiss Axio Imager A2 light microscope. Positively stained cells were counted in 10 fields of view for biopsy specimen at 200x magnification, and the mean value was calculated. Results. The serum level of IL-17 was significantly elevated in patients with CLP, compared with healthy volunteers (0.218±0.221 ng/ml versus 0.126±0.058 ng/ml, respectively; p=0.025). No correlation was found between the serum concentration of IL-17 and patient age, gender, disease duration, extent of skin involvement, the presence or intensity of pruritus, and coexistence of mucosal lesions. In tissue samples from CLP lesions, significantly higher numbers of cells expressing IL-17 were found when compared to a healthy skin (p<0.001). Conclusion. Elevated serum concentration of IL-17 and high expression in a lesional skin support the hypothesis that IL-17 is implicated in the immunopathogenesis of CLP. These findings may constitute a premise for the future use of anti-IL-17 monoclonal antibodies in the treatment of severe and recalcitrant forms of CLP.

Can Osteopontin Be Considered a Biomarker for Endometriosis?

2017 ◽  
Vol 68 (9) ◽  
pp. 2132-2134
Author(s):  
Daniela Roxana Albu (Matasariu) ◽  
Elena Mihalceanu ◽  
Alina Pangal ◽  
Carmen Vulpoi ◽  
Mircea Onofriescu ◽  
...  
Keyword(s):  
Serum Level ◽  
Immunosorbent Assay ◽  
Pelvic Pain ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Multifactorial Disease ◽  
Elisa Kit ◽  
Healthy Women ◽  
Progesterone Treatment ◽  
Large Dispersion

Endometriosis is a multifactorial disease that is manifested by infertility and pelvic pain. The purpose of the study was to evaluate the effect of progesterone treatment on the serum level of osteopontin, a multipotent cytokine, in patients with endometriosis. The study was prospective and we evaluated osteopontin levels that were measured in the serum of 40 patients with endometriosis and 12 healthy women using a standardized Enzyme-Linked Immunosorbent Assay (ELISA) kit. Osteopontin seric levels were lower in endometriosis patients and increased after progesterone treatment. Because of the large dispersion of data even in the control group, we find the association between osteopontin and endometriosis questionable.

scholarly journals Elevated Serum Level of Interleukin 17 in a Population With Prehypertension

2015 ◽  
Vol 17 (10) ◽  
pp. 770-774 ◽  
Author(s):  
Wei Yao ◽  
Yuemin Sun ◽  
Xuechun Wang ◽  
Kaijun Niu
Keyword(s):  
Serum Level ◽  
Elevated Serum ◽  
Interleukin 17 ◽  
Elevated Serum Level

scholarly journals Role of interleukin-10 and interleukin-24 in the pathogenesis of В-cell chronic lymphocytic leukemia

2018 ◽  
pp. 56-61
Author(s):  
Т.Н. Жевак ◽  
Н.П. Чеснокова ◽  
Т.В. Шелехова ◽  
О.Е. Царева ◽  
И.А. Будник ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Serum Level ◽  
B Cell ◽  
Serum Levels ◽  
Lymphocytic Leukemia ◽  
Disease Stage ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Patient Groups ◽  
Cell Chronic Lymphocytic Leukemia

Цель. Изучить закономерности изменения экспрессии интерлейкина-10 и интерлейкина-24, обладающих иммуномодулирующим эффектом, при развитии B-клеточного хронического лимфолейкоза. С учетом этого выявить информативные прогностические критерии развития гемобластоза и/или нового подхода к терапии заболевания. Методы. У 120 больных с разными стадиями В-клеточного хронического лимфолейкоза методом твердофазного иммуноферментного анализа исследована динамика уровней интерлейкина-10 и интерлейкина-24 в сыворотке крови. Результаты. Обнаружено закономерное повышение содержания интерлейкина-10 и интерлейкина-24 в сыворотке крови пациентов уже на начальной стадии B-клеточного хронического лимфолейкоза и сохранение их достоверно высоких уровней на последующих стадиях заболевания. Заключение. Обнаруженный нами факт повышения содержания интерлейкина-10 в сыворотке крови пациентов с В-клеточным хроническим лимфолейкозом является фактором риска снижения противоопухолевой защиты организма вследствие подавления им механизмов клеточного иммунитета и способности ингибировать апоптоз малигнизированных клеток. Напротив, повышение экспрессии интерлейкина-24, обладающего проапоптотической активностью и стимулирующего дифференцировку клеток, может способствовать повышению эффективности механизмов противоопухолевой резистентности организма. Устранение дисбаланса продукции и/или содержания указанных цитокинов в сыворотке крови может создать условия повышения эффективности терапии пациентов с В-клеточным хроническим лимфолейкозом. Aim. To study serum levels of immunosuppressive cytokines (interleukin (IL)-10 and IL-24) in patients with B-cell chronic lymphocytic leukemia for assessment of the disease progression and elaboration of a new treatment strategy. Methods. 120 patients with B-cell chronic lymphocytic leukemia were enrolled in the study and divided into four groups according to the disease stage (Rai stage I-IV). Control group included 30 healthy volunteers. Concentrations of IL-10 and IL-24 were measured in serum using the enzyme-linked immunosorbent assay (ELISA). Results. Serum levels of IL-10 and IL-24 levels were significantly increased in all patient groups compared to the control. No difference in the cytokines levels between the patient groups was observed. Conclusion. In patients with B-cell chronic lymphocytic leukemia, the increased serum level of IL-10 might impair the antitumor defence by inhibiting the cell immune response and preventing apoptosis of malignant lymphocytes. On the other hand, the increased serum level of IL-24 might oppose these effects by promoting cellular differentiation and inducing apoptosis in malignant cells. Therefore, correction of IL-10/IL-24 imbalance may be a beneficial therapeutic strategy for patients with B-cell chronic lymphocytic leukemia.

scholarly journals Activated Human Valvular Interstitial Cells Sustain Interleukin-17 Production To Recruit Neutrophils in Infective Endocarditis

2015 ◽  
Vol 83 (6) ◽  
pp. 2202-2212 ◽  
Author(s):  
Chiou-Yueh Yeh ◽  
Chia-Tung Shun ◽  
Yu-Min Kuo ◽  
Chiau-Jing Jung ◽  
Song-Chou Hsieh ◽  
...  
Keyword(s):  
Infective Endocarditis ◽  
Th17 Cells ◽  
Elevated Serum ◽  
Interstitial Cells ◽  
Orphan Receptor ◽  
Enzyme Linked Immunosorbent Assay ◽  
Interleukin 17 ◽  
Dependent Manner ◽  
Valvular Interstitial Cells ◽  
Chemokine Production

The mechanisms that underlie valvular inflammation in streptococcus-induced infective endocarditis (IE) remain unclear. We previously demonstrated that streptococcal glucosyltransferases (GTFs) can activate human heart valvular interstitial cells (VIC) to secrete interleukin-6 (IL-6), a cytokine involved in T helper 17 (Th17) cell differentiation. Here, we tested the hypothesis that activated VIC can enhance neutrophil infiltration through sustained IL-17 production, leading to valvular damage. To monitor cytokine and chemokine production, leukocyte recruitment, and the induction or expansion of CD4+CD45RA−CD25−CCR6+Th17 cells, primary human VIC were culturedin vitroand activated by GTFs. Serum cytokine levels were measured using an enzyme-linked immunosorbent assay (ELISA), and neutrophils and Th17 cells were detected by immunohistochemistry in infected valves from patients with IE. The expression of IL-21, IL-23, IL-17, and retinoic acid receptor-related orphan receptor C (Rorc) was upregulated in GTF-activated VIC, which may enhance the proliferation of memory Th17 cells in an IL-6-dependent manner. Many chemokines, including chemokine (C-X-C motif) ligand 1 (CXCL1), were upregulated in GTF-activated VIC, which might recruit neutrophils and CD4+T cells. Moreover, CXCL1 production in VIC was induced in a dose-dependent manner by IL-17 to enhance neutrophil chemotaxis. CXCL1-expressing VIC and infiltrating neutrophils could be detected in infected valves, and serum concentrations of IL-17, IL-21, and IL-23 were increased in patients with IE compared to healthy donors. Furthermore, elevated serum IL-21 levels have been significantly associated with severe valvular damage, including rupture of chordae tendineae, in IE patients. Our findings suggest that VIC are activated by bacterial modulins to recruit neutrophils and that such activities might be further enhanced by the production of Th17-associated cytokines. Together, these factors can amplify the release of neutrophilic contentsin situ, which might lead to severe valvular damage.

scholarly journals The Role of Soluble L-Selectin with Polymorphism in Iraqi Arabs Patients with Diabetes Mellitus Type 2

2018 ◽  
Vol 9 (01) ◽  
Author(s):  
Asmaa M. Salih Almohaidi ◽  
Kebaa Ahmed Saeed
Keyword(s):  
Diabetes Mellitus ◽  
Serum Level ◽  
Healthy Subjects ◽  
Diabetes Mellitus Type 2 ◽  
The Body ◽  
Diabetes Mellitus Type ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group

Diabetes mellitus type 2 [DMT2] is a disturbance of metabolism and complex diseases influenced by environmental, genetic agents, and linked with inflammation, happens when the pancreas either does not use the insulin as it should or the body does not make enough insulin, lead to insulin resistance [IR] alongside with gradual loss of ß-cell secretory ability. The aim of this study was to investigate the role of soluble L-selectin (sL-selectin) in diabetes mellitus type 2 patients in Iraqi Arabs patient. Study includes seventy six Iraqi Arabs patients (male and female) having newly diagnosed type 2 diabetes mellitus (T2DM), with Fifty three Iraqi Arabs healthy subjects matched in age, sex and ethnic group. Patients and healthy subjects were genotyped, by PCR-RFLP analysis, and mesure serum level of L-selectin by enzyme-linked immunosorbent assay (sandwich ELISA) test include 65 patients and 23 controls. The statistical analysis of serum level of sL-selectin in study groups showed that the mean of sL-selectin level high significantly increased in patients group (10.708±1.1007) compared to control group (7.055±0.767) respectively. Thus, our results suggest soluble L-selectin play a role in the development of DMT2 in Iraqi Arabs patients. Present results showed that genotype PS associated with increase the susceptibility of DMT2.

Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma.

1995 ◽  
Vol 13 (3) ◽  
pp. 575-582 ◽  
Author(s):  
J F Seymour ◽  
M Talpaz ◽  
F Cabanillas ◽  
M Wetzler ◽  
R Kurzrock
Keyword(s):  
Overall Survival ◽  
Interleukin 6 ◽  
Cell Lymphoma ◽  
Prognostic Significance ◽  
Elevated Serum ◽  
Large Cell ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Diffuse Large Cell Lymphoma ◽  
Large Cell Lymphoma

PURPOSE Interleukin-6 (IL-6) is a potent immunomodulatory cytokine that may have pathogenetic and prognostic significance in a number of disorders. The objective of this study was to examine the correlation between serum IL-6 levels and phenotypic characteristics, as well as outcome of patients with diffuse large-cell lymphoma (DLCL). PATIENTS AND METHODS Using an enzyme-linked immunosorbent assay (ELISA; lower limit of sensitivity, 0.35 pg/mL), we measured IL-6 levels in frozen sera from 33 healthy controls and 58 untreated patients with DLCL who were enrolled onto a single combination chemotherapy protocol. Serum IL-6 levels were correlated with clinical and laboratory features at diagnosis and with failure-free and overall survival. RESULTS Serum IL-6 levels in the lymphoma patients (median, 4.37 pg/mL; range, < 0.35 to 110 pg/mL) were significantly higher than in the control group (median, < 0.35 pg/mL; range, < 0.35 to 1.87 pg/mL) (P < .0001). Serum IL-6 levels were higher in patients with B symptoms (P = .012), an elevated beta 2-microglobulin level (> or = 3.0 mg/L) (P = .017), and a poor performance status (P = .02). Direct linear correlations with the erythrocyte sedimentation rate (ESR), platelet count, and total WBC count, and an inverse linear correlation with the serum albumin level, were observed (all P < .02). Patients with elevated serum IL-6 levels had inferior failure-free (P = .042) and overall survival (P = .05) compared with those with normal serum IL-6 levels. CONCLUSION In patients with DLCL, elevated serum levels of IL-6 at diagnosis are frequent, strongly associated with many adverse disease features, and predictive of a poor failure-free and overall survival.

Serum IL-6 as a prognostic biomarker in patients with stage IIB-III melanoma.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 8545-8545
Author(s):  
Lise Hoejberg ◽  
Lars Bastholt ◽  
Julia S. Johansen ◽  
Ib Jarle Christensen ◽  
Merete Krogh ◽  
...  
Keyword(s):  
Confidence Interval ◽  
Serum Concentration ◽  
Prognostic Biomarker ◽  
Negative Impact ◽  
White Blood Cells ◽  
Elevated Serum ◽  
Primary Melanoma ◽  
Control Group ◽  
Prognostic Impact ◽  
Pretreatment Serum

8545 Background: Interleukin (IL)-6 is an immunomodulatory cytokine produced by cancer cells and different immune cells. The specific function of IL-6 in cancer is unknown. Serum IL-6 is elevated in patients with different types of cancer. Elevated serum concentration of IL-6 is related to short survival in patients with stage IV melanoma. Methods: IL-6 was measured by ELISA (R&D) in pretreatment serum samples from 435 patients with stage IIB-III melanoma (151 women and 284 men, median age 51 years, range 18-77). After surgery patients were treated in a randomized study (The Nordic IFN trial) with either adjuvant interferon for 1 or 2 years, or observation. Results: Median serum concentration of IL-6 after surgery and before treatment was 1.8 ng/l, range 0.23-24 ng/l. Patients with serum IL-6 above the median had shorter overall survival (OS) compared to patients with serum IL-6 below the median (p=0.004). Median OS was 4.5 years in patients with serum IL-6 above the median (95% confidence interval (CI): 3.05-7.60). In patients with serum IL-6 below the median, median OS was not reached at the last survival-update. Multivariate Cox analysis including serum IL-6, ulceration in primary melanoma, LDH, white blood cells, lymph node metastases and Breslow thickness of primary melanoma showed that only serum IL-6 (hazard ratio (HR) = 1.48, 95% confidence interval (CI) : 1.13-1.94, p=0.004) was an independent prognostic factor for OS. In subgroup analysis of the control group and the two treatment groups, serum IL-6 demonstrated a negative prognostic impact in the control group (HR = 1.62, 95% CI: 1.02-2.57, p=0.04) and in the group treated with 2 years interferon HR = 1.69, 95% CI: 1.06-2.7, p=0.03). In the group treated with 1 year interferon this negative impact was not significant (HR = 1.15, 95% CI: 0.71-1.85, p=0.58). An interaction between IL-6 and treatment arm was not significant (p=0.45), suggesting that the negative prognostic effect of elevated pretreatment serum IL-6 is independent of treatment. Conclusions: Serum IL-6 above the median is an independent prognostic biomarker of short OS in patients operated for stage IIB-III melanoma.

scholarly journals Association of Ki-67 Labelling Index and IL-17A with Pituitary Adenoma

2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
Brigita Glebauskiene ◽  
Rasa Liutkeviciene ◽  
Alvita Vilkeviciute ◽  
Inga Gudinaviciene ◽  
Aurelija Rocyte ◽  
...  
Keyword(s):  
Pituitary Adenoma ◽  
Pituitary Adenomas ◽  
Immunohistochemical Analysis ◽  
Serum Levels ◽  
Labelling Index ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Ki 67 ◽  
Tissue Samples ◽  
Median Serum

The aim of the present study was to determine if the Ki-67 labelling index reflects invasiveness of pituitary adenoma and to evaluate IL-17A concentration in blood serum of pituitary adenoma patients. The study was conducted in the Hospital of Lithuanian University of Health Sciences. All pituitary adenomas were analysed based on magnetic resonance imaging findings. The suprasellar extension and sphenoid sinus invasion by pituitary adenoma were classified according to Hardy classification modified by Wilson. Knosp classification system was used to quantify the invasion of the cavernous sinus. The Ki-67 labelling index was obtained by immunohistochemical analysis with the monoclonal antibody, and serum levels of IL-17A were determined by enzyme-linked immunosorbent assay (ELISA). Sixty-nine PA tissue samples were investigated. Serum levels of IL–17A were determined in 60 patients with PA and 64 control subjects. Analysis revealed statistically significantly higher Ki-67 labelling index in invasive compared to noninvasive pituitary adenomas. Median serum IL-17A level was higher in the pituitary adenoma patients than in the control group. Conclusion. IL-17A might be a significant marker for patients with pituitary adenoma and Ki-67 labelling index in case of invasive pituitary adenomas.

Neutrophil Adhesion Molecule Expression and Serum Concentration of Soluble Adhesion Molecules during and after Pediatric Cardiovascular Surgery with or without Cardiopulmonary Bypass

2002 ◽  
Vol 96 (5) ◽  
pp. 1078-1085 ◽  
Author(s):  
Jörg Hambsch ◽  
Pavel Osmancik ◽  
József Bocsi ◽  
Peter Schneider ◽  
Attila Tárnok
Keyword(s):  
Cardiopulmonary Bypass ◽  
Serum Concentration ◽  
Adhesion Molecules ◽  
Adhesion Molecule ◽  
Cardiovascular Surgery ◽  
Interleukin 8 ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Serum Concentrations ◽  
Pediatric Cardiovascular Surgery

Background Increased neutrophil activation by cardiopulmonary bypass (CPB) during cardiovascular surgery is thought to be responsible for postoperative complications. In children, the contribution of cardiovascular surgery alone to this response is not well-characterized. Methods Children undergoing surgery with CPB (CPB group, n = 35) and without CPB (control, n = 22) were studied (age, 3-17 yr). Blood was drawn 24 h preoperatively before medication, after anesthesia, after connection to CPB, at reperfusion, 4 h to 2 days after surgery, at discharge, and months after surgery. Neutrophil antigen expression and serum concentration of adhesion molecules, interleukin 8, and C5a (fragment of C5 complement) were analyzed by flow cytometry and enzyme-linked immunosorbent assay, respectively. Results With and without CPB, anesthesia and surgery induced decreased LFA-1 (CD11a-CD18), Mac-1 (CD11b-CD18), CD45, and CD54 (intercellular adhesion molecule 1) surface expression and sICAM-1 serum concentrations (all P &lt; 0.001). sL-selectin serum concentration decreased with CPB (P &lt; 0.001) but was not significantly altered in the control. In contrast, CD62L expression increased during CPB (P &lt; 0.001). The time course of all analyzed markers was not significantly different between CPB and control, with the exception of sL-selectin (P = 0.017). One-day preoperative baseline values were reached days to months after surgery. Interleukin 8 and C5a serum concentrations increased after surgery in both the CPB group and the control group. Conclusions Pediatric cardiovascular surgery leads to reduced adhesiveness and activity of circulating neutrophils. This reduction is more pronounced and sustained with CPB. These data may be useful in the assessment of novel therapeutic strategies.

scholarly journals Serum vascular endothelial growth factor concentration in dogs diagnosed with chronic superficial keratitis

2014 ◽  
Vol 62 (1) ◽  
pp. 22-32
Author(s):  
Ireneusz Balicki ◽  
Aleksandra Sobczyńska-Rak
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Elevated Serum ◽  
Test Group ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Vascular Endothelial ◽  
Healthy Dogs ◽  
The Right ◽  
Endothelial Growth Factor

The objective of this study was to measure the vascular endothelial growth factor (VEGF) levels in dogs diagnosed with chronic superficial keratitis (CSK). The study was performed on 25 German shepherds (14 males and 11 females, aged between 3 and 11 years). The VEGF levels were determined in blood serum using commercially available enzyme-linked immunosorbent assay (ELISA; Quantikine Canine VEGF Immunoassay, R&D Systems). The test group of affected German shepherds was subdivided into two subgroups, based on the area of corneal neovascularisation. The first subgroup (9 patients) comprised dogs with neovascularisation observed in 1 to 2 quadrants of the right and left cornea, while the second subgroup (16 patients) comprised dogs with neovascularisation observed in 3 to 4 quadrants of the right and left cornea. The control group comprised 12 clinically healthy German shepherds (7 males and 5 females, aged between 3 and 9 years). The results were then statistically analysed by the Mann-Whitney test. The study indicated that the median serum VEGF concentration in healthy dogs was 14.9 pg/mL. The VEGF level observed in sick German shepherds was elevated (19.5 pg/mL) as compared to the values found in healthy dogs; however, a statistically significant increase in VEGF concentration, as compared to the values observed in healthy dogs, was only noted in the first subgroup, where the median VEGF concentration was 22.0 pg/mL. Elevated serum VEGF concentration was observed in German shepherds diagnosed with CSK. A statistically significant increase in VEGF levels was observed in dogs in the first stage of the disease, i.e. the early stage of neovascularisation.

Sign in / Sign up

Export Citation Format

Share Document